



- (51) **International Patent Classification:**
A61K 31/4436 (2006.01) *C12Q 1/68* (2006.01)
- (21) **International Application Number:**
PCT/US2012/020606
- (22) **International Filing Date:**
9 January 2012 (09.01.2012)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/431,370 10 January 2011 (10.01.2011) US
- (71) **Applicants (for all designated States except US):** ZIN-
FANDEL PHARMACEUTICALS, INC. [US/US]; One
Science Drive, Durham, North Carolina 27708 (US).
TAKEDA PHARMACEUTICAL COMPANY LIM-
ITED [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka
541-0045 (JP).
- (72) **Inventors; and**
- (75) **Inventors/Applicants (for US only):** ROSES, Allen D.
[US/US]; 53525 Bickett, Chapel Hill, North Carolina
27517 (US). TANEJA, Rajneesh [US/US]; 821 Pem-
brooke Road, Libertyville, Illinois 60048 (US).
- (74) **Agents:** MAEBIUS, Stephen B. et al.; Foley & Lardner
LLP, 3000 K Street, NW, Suite 600, Washington, District
of Columbia 20007 (US).
- (81) **Designated States (unless otherwise indicated, for every
kind of national protection available):** AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD,
SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States (unless otherwise indicated, for every
kind of regional protection available):** ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) **Title:** METHODS AND DRUG PRODUCTS FOR TREATING ALZHEIMER'S DISEASE




FIG. 1

(57) **Abstract:** Provided herein are drug products with low dose pioglitazone for use in the treatment (e.g., delay of onset) of cognitive impairment of the Alzheimer's type. Methods of manufacture thereof are also provided. Further provided are methods of treatment for Alzheimer's disease including administering a drug product with low dose pioglitazone. The methods may include determining whether the subject is at risk of developing Alzheimer's disease based upon the subject's age and TOMM40 523 genotype.